Gastric esophageal treatment adenocarcinoma (GEA) is a serious health problem that affects the upper digestive system and is usually diagnosed in advanced stages, resulting in poor prognosis. Traditional therapy includes chemotherapy and targeted drugs, but the resistance to these therapies is still a challenge. The latest progress of genetic research emphasizes the importance of understanding the specific mutation that may affect the treatment results. A kind of mutation SMARCA4 plays a vital role in regulating gene expression and maintaining genomic stability, and has explored its impact on GEA in a new study.
This pioneering observation study conducted by Dr. Jaffer Ajani from the University of Texas’s MD Anderson Cancer Center used the genetic landscape of GEA for the next generation of sequencing (NGS) group. This major study was published in journal cancer for peer review.
In this study, SMARCA4MS was identified in a small part of GEA patients. These mutations are significantly correlated with non-sign-nicknamed cell subtype and programming death ligand 1 (PD-L1). Interestingly, there is no significant difference between SMARCA4MS patients and patients expressing normal patients. Dr. Ajani said: “Our research shows that SMARCA4 mutations will not significantly affect the survival results of GEA patients.”
In order to identify the mutations in the SMARCA4 gene, the NGS panel test was adopted. This advanced method allows detecting various genetic changes, including changes in point mutations and copy numbers. These changes and recurrence diseases that require systematic treatment and recurrence of systemic treatment are particularly important. The study includes comprehensive population statistics and clinical data, covering extensive tumor characteristics and biomarker information. This information understands the treatment strategy.
In other genes (such as FANCA, IGF1R, KRAS, FANCL, and PTEN), a significant relationship is found between Smarca4ms and mutations. Most SMARCA4M cases involve unspeaks of single nucleotide variants (SNV), and frequently occur with TP53, KRAS, Arid1a, and ERBB2 mutations. This highlights the complex interaction between SMARCA4 and other genetic changes in GEA.
Dr. Ajani added: “Our discovery emphasizes the necessity of the complicated genetic landscape of GEA and understanding the molecular interaction between various gene mutations.” Treatment strategy pave the way. “
Despite the discovery of important correlations, the study also emphasized the need to conduct further research to fully clarify the clinical significance of SMARCA4 mutations in GEA. Future research should focus on the broader genetic framework of GEA, and combine other genes related to SWI/SNF to better understand its role in the disease.
In short, Dr. Ajani and his colleagues provided valuable insights for the genetic foundation of GEA, emphasizing the importance of personalized medicine in cancer treatment. By revealing the association between SMARCA4 mutations and other genetic changes, their research has opened a new way for developing targeted therapies and improving patients’ prognosis.
Journal reference
Yamashita, K., Sewastjanow-Silva, M., Yoshimura, K., Rogers, JE, Rosa Vicentini, E., POOL PIZZI, M., FAN, YM, Q., WATERS, Re, Wang, L. And Ajani, JA (2024). SMARCA4 mutation in gastric tube adenocarcinoma: observation research conducted through the next -generation sequencing group. Cancer, 16,1300. Doi: https: //doi.org/10.3390/cancers16071300
About the author
Jaffer a. ajaniDoctor of Medicine is a medical professor and internal medicine professor at UTMDACC and professor of internal medicine. His main interest is GI tumor research, especially focusing on gastric and esophageal cancer. Dr. Ajani obtained the board certification of the board of directors of family medicine and internal medicine and medical oncology.
Dr. Ajani obtained a PhD in Medicine from the Government Medical College of Nagipur, India in 1971. Family practice. Then, he completed the internship and residential place of internal medicine at Tulland University of Medicine, and then obtained clinical research on medical oncology at the MD Anderson Cancer Center. He has completed two years of medical oncology research scholarships. He became a teacher of UTMDACC in 1982 and stayed at the institution. He has a large number of clinical practice and his own laboratory. There are more than 600 peer review publications in his mother and horse. Since 2007, he has been awarded several DOD and NCI funds, and his funds will be extended to 2027. He was named Giantofcancer.com (Giantofcancer.com), who was rated as gastrointestinal cancer in 2022. He was an ASCO researcher and was rated as the best doctor in the United States. Since 1991. He participated in many countries and international communities. He is the chairman of the gastric cancer and esophageal cancer guidelines of the national comprehensive cancer network, and has a history of more than 25 years.
Matheus sewastjanow-silvaDoctor of Medicine has always been a research investigator at UTMDACC, a doctor of Medicine at the University of Texas. He ranked second in his motherland, and his translation and clinical cancer research project was graduated from the first semester until 2018. Studies, Dr. Sewastjanow-Silva is a primary health doctor who is a vulnerable group including indigenous people. He also worked in the hospital and played an important role in public health management during the COVID-19 popular period. In his recent scientific efforts, Dr. Sewastjanow-Silva participated in a number of clinical trials and studied the role of various cancer biomarkers and new monoclonal antibody therapy.
